Assessing mean apnea-hypopnea duration (MAD) in patients with OSA yields hypoxemia and symptom burden data not provided by the AHI or ODI.

Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...

Early management of obstructive sleep apnea in patients with IPF could slow disease progression and improve outcomes.

At World Sleep 2025, Robson Capasso, MD, of Stanford University in California, challenged the field's reliance on the apnea-hypopnea index (AHI) as the primary measure of treatment success in ...

Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition ...

Credit: Getty Images Obstructive sleep apnea may significantly increase the risk for coronary artery disease, atrial fibrillation, cerebrovascular accident, and congestive heart failure. Obstructive ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Please provide your email address to receive an email when new articles are posted on . In an adjusted model, there was a significant link between long-term PM 10 exposure and apnea-hypopnea index.

A middle-age woman with high blood pressure and epilepsy gained 50 lb over the course of 2 years. What was the best approach to diagnosing her problem? The solution was to sleep on it, said Nancy ...

Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should ...

Along with diet and exercise, sleep is the third pillar of health. And frankly, a good night's sleep is often the answer to whatever ails you. But for 30 million people in the United States, sleep ...